Ceryvyn Therapeutics Limited
CKDXF
Other OTC0.01
USD
- -
- -
CIK
0001815620
ISIN
AU0000478117
Return %
Stock
S&P500
1Y
-97.73
19.01
3Y
-97.62
65.48
5Y
-99.08
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Level 9 Melbourne VIC Australia 3000
- IPO Date
- Oct 25, 2011
- CIK
- 0001815620
- Website
- ceryvyn.com
- Similar Companies
- Business
- Opthea Limited is a clinical-stage biopharmaceutical company headquartered in South Yarra, Australia, specializing in developing novel biological therapeutics for the treatment of progressive retinal diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its primary product candidate is sozinibercept (OPT-302), a first-in-class VEGF-C/D trap inhibitor designed to be used in combination with standard anti-VEGF-A therapies to improve visual outcomes in patients with wet AMD and DME. The company’s proprietary technology targets vascular endothelial growth factors involved in pathological blood and lymphatic vessel growth and vascular leakage, aiming to address significant unmet medical needs in retinal diseases. Founded in 2004, Opthea operates primarily in Australia and the United States within the biotechnology and healthcare sectors. In recent developments, Opthea discontinued the Phase 3 COAST and SHORE clinical trials for sozinibercept in wet AMD after the trials failed to meet their primary endpoints, leading to a strategic reassessment of its clinical pipeline. The company executed a major corporate restructuring in 2025, including an over 80% workforce reduction and over 50% downsizing of its board of directors to reduce operating costs and extend its cash runway. Concurrently, Opthea settled a development funding agreement for a $20 million cash payment and issuance of 9.99% equity, replacing a potential $680 million liability. These moves aimed to maintain financial stability, with approximately $20 million in cash retained post-settlement. Additionally, chief executive and financial officers departed in 2025, with the chairman assuming CEO responsibilities. Opthea is currently undertaking a strategic review to explore targeted internal development, business development, licensing partnerships, or potential capital return to shareholders. Opthea’s focus remains on advancing its novel retinal disease therapies through clinical validation and regulatory pathways, aiming to provide improved vision outcomes and quality of life to patients globally. The company’s intellectual property portfolio encompasses VEGF-C, VEGF-D, and VEGF receptor-3 targets. It continues to collaborate strategically and adapt its business model to maintain position within the retinal disease treatment landscape. This comprehensive approach situates Opthea Limited as a focused clinical-stage biopharmaceutical firm dedicated to innovation in retinal therapeutics, with recent operational and strategic shifts reflecting an effort to stabilize and refocus in the wake of clinical trial challenges. The company’s activities currently prioritize retention of its core novel therapy assets and exploration of strategic options for future growth and development in the biotechnology sector.